We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Therapeutic Application of Allogeneic Fetal Membrane-Derived Mesenchymal Stem Cell Transplantation in Regenerative Medicine

Shin Ishikane¹, Hiroshi Hosoda¹ and Tomoaki Ikeda^{1,2}

¹*Department of Regenerative Medicine and Tissue Engineering,
National Cerebral and Cardiovascular Center Research Institute,*

²*Department of Perinatology and Gynecology,
National Cerebral and Cardiovascular Center,
Japan*

1. Introduction

In 1968, Friedenstein et al. isolated clonogenic spindle-shaped cells from bone marrow (BM) in monolayer cultures, which they called colony-forming-unit fibroblasts (Friedenstein et al., 1974). These cells showed the ability to self-renew and to differentiate toward a mesodermal lineage as adipocytes, chondrocytes, osteocytes and connective stromal cells. Several studies reported that BM-derived multipotential stromal precursor cells can also differentiate into lineages such as ectodermal cells and endodermal cells (Kopen et al., 1999; Pittenger et al., 1999). For this reason, BM-derived stromal cells were first considered to be stem cells by Caplan and were named mesenchymal stem cells (MSCs) (Caplan, 1991). The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposed the following minimal criteria for defining human MSCs: (1) MSCs must be plastic-adherent when maintained under standard culture conditions, (2) MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules, (3) MSCs must differentiate into osteoblasts, adipocytes and chondroblasts *in vitro* (Dominici et al., 2006; Sensebe et al., 2010).

MSCs have been obtained from adipose tissue, cord blood and many other tissues, and can differentiate into a variety of cells, including adipocytes, osteocytes, chondrocytes, endothelial cells and myocytes (Campagnoli et al., 2001; Kim et al., 2006; Zuk et al., 2001). MSCs secrete a variety of angiogenic, antiapoptotic and mitogenic factors, such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and insulin-like growth factor-1 (IGF-1) (Kinnaird et al., 2004; Nagaya et al., 2005). Among MSCs derived from various tissues, BM-derived MSCs (BM-MSCs) are widely used in the field of stem cell transplantation. We previously reported that autologous BM-MSC transplantation induced therapeutic angiogenesis in a rat model of hind-limb ischemia and improved cardiac function in rat models of dilated cardiomyopathy and acute autoimmune myocarditis (Iwase et al., 2005; Nagaya et al., 2005; Ohnishi et al., 2007). However, there are several limitations to using an autologous cell source for cell transplantation, such as the

invasiveness of the cell collection procedure, inadequate numbers of cells and donor-site morbidity, and the functionality of precursor cells in patients with cardiovascular risk factors has been questioned. The frequency and differentiation capacity of BM-MSCs decrease with age (D'Ippolito et al., 1999; Mareschi et al., 2006). An alternative source of MSCs that could provide large quantities of cells would be advantageous. One way to circumvent these limitations could be to use allogeneic MSCs. If allogeneic MSCs could be isolated from healthy young donors, and if they had a therapeutic effect similar to that of autologous MSCs, they would be considered a superior new cell source because it would be possible to overcome the problems noted above, and wider clinical applications of cell therapy would become available. Therefore, we focused on fetal membranes (FMs), which are generally discarded as medical waste after delivery, as an alternative source of autologous MSCs. Several studies reported that human FMs contain multipotent cells similar to BM-MSCs and are easy to expand (Alviano et al., 2007; In't Anker et al., 2004; Portmann-Lanz et al., 2006). If FM-MSCs could be used in allogeneic transplantation, FMs would be a useful source of cells for transplantation and regenerative medicine.

In this review, we compare the cellular characteristics and utilization of FM-MSCs with those of BM-MSCs and discuss the potential of allogeneic FM-MSC transplantation therapy in the tissue regeneration (Ishikane et al. 2008, 2010).

2. Fetal membrane-derived mesenchymal stem cells

The two FMs, the amnion and the chorion, marginate outward from the basal surface of the placenta and encase the amniotic fluid in which the fetus is suspended during pregnancy. The FMs facilitate gas and waste exchange and play a critical role as defense barriers, in maintenance of pregnancy and in parturition (Bourne, 1962). Human FMs, which are generally discarded as medical waste after delivery, were recently shown to be rich sources of MSCs. Because fetal tissues are routinely discarded postpartum, FMs are inexpensive and easy to obtain and their availability is virtually limitless, avoiding the need for mass tissue banking. Human amnion membrane-derived MSCs (hAM-MSCs) were isolated for the first time from second and third trimester AMs by In't Anker et al., who demonstrated their potential for differentiation into osteogenic and adipogenic cells (In't Anker et al., 2004). Later, Portmann-Lanz et al. demonstrated their capacity for differentiation into chondrogenic, myogenic and neurogenic lines (Portmann-Lanz et al., 2006). In 2007, Alviano et al. reported that hAM-MSCs are superior in proliferation and differentiation potential to adult hBM-MSCs, providing the first evidence of the angiogenic potential of hAM-MSCs (Alviano et al., 2007). A large quantity of MSCs was isolated from hFMs by serial passaging them prior to senescence at about 15 passages (Kim et al., 2007; Soncini et al., 2007). The availability of a fetal tissue that is usually discarded without any ethical conflict and the high yield in stem cell recovery make FMs a truly exciting alternative source that offers new prospects for expanding the range of clinical applications for stem cells.

In our study, FM-MSCs derived from Lewis rats did not express the hematopoietic or endothelial surface markers CD11b/c, CD31, CD34 and CD45, but stained positive for CD29, CD73 and CD90 (Ishikane et al., 2008). These rat FM-MSCs differentiated into adipocytes, osteocytes and chondrocytes (Figure 1). In culture medium, FM-MSCs secreted the angiogenic factors, VEGF and HGF. In an angiogenic gene polymerase chain reaction array analysis, FM-

MSCs expressed compounds characteristic of several angiogenesis-related genes, including VEGF-C, platelet-derived growth factor-B, angiopoietins, chemokines and interleukins. These results show that FM-MSCs have properties similar to those of BM-MSCs and suggest that transplantation of FM-MSCs may induce therapeutic angiogenesis in cases of ischemic disease.

Fig. 1. Characterization of FM-MSCs and BM-MSCs: (A) Morphology of FM-MSCs and BM-MSCs derived from Lewis rats. In the early passages, FM- and BM-MSC derived cells appeared microscopically heterogeneous. After several passages, these cells formed a morphologically homogenous population of fibroblast-like cells, which was similar to BM-MSCs. Scale bars: 100 μm . (B) Multipotency of FM-MSCs and BM-MSCs. Differentiation into adipocytes was observed by oil red O. Differentiation into osteocytes was observed by alizarin red S. Differentiation into chondrocytes was observed by safranin O. Scale bars: 50 μm . (C) Flow cytometric analysis of FM-MSCs and BM-MSCs at passage 3. Closed areas indicate staining with a specific antibody, whereas open areas represent staining with isotype control antibodies.

FM-MSc	Characteristic	BM-MSc
Noninvasive	MSc harvest procedure	Invasive
Placenta	Donor tissue	Adult bone marrow
High	Number of obtained cells	Low
CD11–, CD29+, CD31–, CD34–, CD45–, CD73+, CD90+, MHC class I+, MHC class II–	Immunophenotype	CD11–, CD29+, CD31–, CD34–, CD45–, CD73+, CD90+, MHC class I+, MHC class II–
Adipogenic Osteogenic Chondrogenic	In vitro multipotency	Adipogenic Osteogenic Chondrogenic
VEGF, HGF	Growth factor secretion	VEGF, HGF, IGF-1, adrenomedullin
In hind limb ischemia: induced In acute myocarditis: not	Angiogenesis	In hind limb ischemia: induced In acute myocarditis: induced
Low	Engraftment of transplanted cells	Low
Vascular endothelial cells: none Myocardium: none	In vivo differentiation	Vascular endothelial cells: very low or none Smooth muscle cells: very low Myocardium: very low
Evade	Alloreactive T cell activation (rejection)	Evade
Suppress	CD4+T cell activation (immunomodulatory effect)	Suppress
Suppress	Fibrosis	Suppress
Suppress	Inflammatory cell infiltration	Suppress

Table 1. Comparison of the characteristics of FM-MSCs and BM-MSCs observed in our studies. Abbreviations: BM-MSc, bone marrow-derived mesenchymal stem cell; FM-MSc, fetal membrane-derived mesenchymal stem cell; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor-1; MSc, mesenchymal stem cell; MHC, major histocompatibility complex; VEGF, vascular endothelial growth factor.

2.1 Immunomodulatory effect of fetal membrane-derived mesenchymal stem cells

MSCs have received renewed interest, particularly for their use in transplantation medicine. Although the main driving force responsible for interest in the regenerative capacity of MSCs in the past was their presumptive plasticity, their ability to modulate the immune response is now attracting greater interest. MSCs are positive for major histocompatibility complex (MHC) class I but negative for MHC class II and for costimulatory factors such as CD40, CD80 and CD86, and are therefore considered nonimmunogenic (Chamberlain et al.

2007). Allogeneic BM-MSC transplantation has been used in several preclinical and clinical studies, in which allogeneic MSCs were not rejected in the absence of immunosuppression (Amado et al., 2005; Hare et al., 2009; Le Blanc et al., 2008).

The use of BM-MSCs not only avoids allogeneic rejection but also may confer immunosuppressive effects. Several studies demonstrated that MSCs modulate the function of T cells, major executors of the adaptive immune response (Krampera et al., 2003; Le Blanc et al., 2003). Di Nicola et al. showed that BM-MSCs strongly suppressed T cell proliferation in a mixed lymphocyte culture (MLC) test (Di Nicola et al., 2002).

In our study of rats, FM-MSCs had immunological properties similar to those of BM-MSCs. In an MLC test with haplotype-mismatched allogeneic cells, FM-MSCs did not provoke alloreactive lymphocyte proliferation. Interleukin (IL)-2 plays a role in the activation and proliferation of T cells. IL-2 concentrations in supernatants of FM-MSC and allogeneic lymphocyte co-cultures and in the MLC were lower than those in lymphocyte and allogeneic lymphocyte co-cultures.

To investigate T cell alloreactivity to transplanted allogeneic FM-MSCs, FM-MSCs, BM-MSCs or splenic lymphocytes obtained from GFP-transgenic Lewis rats were injected into the hind-limb tissue of MHC-mismatched August-Copenhagen Irish (ACI) rats. One week after cell injection, slight T cell infiltration was observed at the injection site of allogeneic FM-MSC-injected hind-limb muscles, but the degree of infiltration was less marked than that after allogeneic splenic lymphocyte transplantation and was equivalent to that induced by allogeneic BM-MSCs. Use of non-autologous cells for transplant also requires that one consider the possibility of graft rejection. Although most clinical applications of FM-MSC transplantation apply to allogeneic transplantation, our results suggest that FM-MSCs evade T cell alloreactivity and may be successfully transplanted across MHC barriers.

2.2 Therapeutic angiogenesis in allogeneic fetal membrane-derived mesenchymal stem cell transplantation in a hind-limb ischemia model

Therapeutic angiogenesis, a strategy to treat tissue ischemia by promoting the proliferation of collateral vessels, has emerged as one of the most promising therapies developed to date (Carmeliet, 2003). In a rat model of hind-limb ischemia, autologous BM-MSC transplantation enhanced angiogenesis and peripheral blood flow in the ischemic limb, and these cells were incorporated into sites of angiogenesis after tissue ischemia (Iwase et al., 2005). MSC transplantation was shown to be a promising approach for restoring tissue vascularization after ischemic events (Moon et al., 2006; Nakagami et al., 2005).

In a previous study, we demonstrated that allogeneic transplantation of FM-MSCs induced angiogenesis in a rat model of hind-limb ischemia (Ishikane et al., 2008). One day after left common iliac artery resection, FM-MSCs obtained from Lewis rats were transplanted into the ischemic thigh muscle of MHC-mismatched ACI rats with hind-limb ischemia (5×10^5 cells/animal). The blood perfusion of the ischemic limb and the capillary density of the ischemic muscle were increased 2 and 3 weeks, respectively, after allogeneic FM-MSC transplantation (Figure 2). It is noteworthy that the therapeutic gain was similar to that of allogeneic BM-MSC transplantation.

Fig. 2. Comparison of angiogenesis after allogeneic FM-MSC and BM-MSC transplantation in rats with hindlimb ischemia

(A) Representative examples of serial A laser doppler perfusion image (LDPI). Blood perfusion of the ischemic hindlimb was markedly increased in the allogeneic FM-MSCs and BM-MSCs transplanted group 3 weeks after cell injection (red to orange). (B) Quantitative analysis of hindlimb blood perfusion. LDPI index was significantly higher in the allogeneic FM-MSCs and BM-MSCs transplanted groups than in the phosphate-buffer saline (PBS) treated control group 3 weeks after cell injection. The LDPI index was determined as the ratio of ischemic to nonischemic hindlimb blood perfusion. Data are mean $\pm$ S.E.M. * $P < 0.05$ FM-MSC vs. PBS; † $P < 0.05$ BM-MSC vs. PBS.

The allogeneic FM- and BM-MSCs in the ischemic hind-limb tissue survived for 3 weeks after transplantation, but the number of engrafted cells decreased significantly in both cases (Figure 3). In a previous trial, intramuscularly transplanted allogeneic BM-MSCs were observed 6 months after transplantation (Dai et al., 2005). In other studies, the number of engrafted autologous and allogeneic MSCs gradually decreased, and MSCs were absent after several weeks (Fouillard et al., 2007; Kraitchman et al., 2005; Shake et al., 2002). Muller-Ehmsen et al. reported the observed transplanted MSC loss was predominantly caused by cell death rather than migration of cells to other organs (Muller-Ehmsen et al., 2006).

To investigate differentiation of transplanted FM-MSCs into blood vessel endothelial cells, we performed immunofluorescent staining of MSC-transplanted ischemic hind-limb sections. GFP-positive transplanted FM-MSCs and BM-MSCs and lectin-positive endothelial cells were observed in hind-limb tissue, but GFP/lectin double-positive cells were not observed. Some studies reported that transplanted BM-MSCs directly differentiated into the vascular endothelial cells and vascular smooth muscles in ischemic models (Al-Khaldi et al., 2003; Moon et al., 2006). However, recent studies demonstrated that the direct contribution of grafted MSCs is minimal or even absent, and that paracrine actions are of major importance in mediating their regenerative effects (Aranguren et al., 2008; Au et al., 2008; Muller-Ehmsen et al., 2006). MSCs were considered to induce neovascularization by

secreting large amounts of humoral factors involved in angiogenesis, such as VEGF and HGF (Kinnaird et al., 2004; Nagaya et al., 2005). VEGF is one of the more powerful angiogenic cytokines and can also mobilize endothelial progenitor cells (EPCs) from BM and inhibit EPC apoptosis (Asahara et al., 1999). HGF plays important roles in tissue regeneration, morphogenesis and angiogenesis (Zarnegar and Michalopoulos, 1995). HGF is thought to stimulate endothelial cell proliferation and to induce angiogenesis, and is a key signaling factor that promotes infiltration of circulating stem cells from the peripheral circulation to an ischemic area (Morishita et al., 1999; Weimar et al., 1998). Further studies are needed to improve the availability of transplanted MSCs for engraftment, but allogeneic FM-MSC transplantation could provide a new therapeutic strategy for the treatment of severe peripheral vascular disease.

2.3 Immunomodulatory effect of allogeneic fetal membrane-derived mesenchymal stem cell transplantation in an autoimmune myocarditis model

Several studies reported that MSCs have immunomodulatory effects mediated by secretion of soluble factors such as prostaglandin E₂, indoleamine 2,3-dioxygenase, IL-6, IL-10, heme oxygenase-1 and galectin (Aggarwal and Pittenger, 2005; Chabannes et al., 2007; Meisel et al., 2004; Sioud et al., 2011). Based on the immunomodulatory property of MSCs, allogeneic FM-MSC transplantation may be an attractive treatment for autoimmune myocarditis.

Experimental autoimmune myocarditis (EAM) is induced by injecting porcine cardiac myosin in Lewis rats. Allogeneic FM-MSCs obtained from MHC-mismatched ACI rats (5×10^5 cells/animal) were transplanted intravenously into EAM rats 1 week after myosin injection. Two weeks after transplantation, the intravenous allogeneic transplantation of FM-MSCs reduced fibrosis, edema, necrosis, granulation and eosinophil infiltration in hearts exhibiting EAM and significantly attenuated infiltration of inflammatory cells (CD68-positive monocytes and macrophages) and MCP-1 expression in the myocardium (Figure 4A and B). Hemodynamic and echocardiographic tests showed a significant improvement in cardiac function as a result of allogeneic FM-MSC transplantation (Ishikane et al., 2010). The extent of the improvement ranged from 30% to 60% according to various indices of the level of dysfunction, which is equivalent to that observed in our previous study on autologous BM-MSC transplantation in EAM (Ohnishi et al., 2007). Allogeneic transplantation of FM-MSCs significantly reduced infiltration of T cells (CD3-positive cells) into EAM hearts (Figure 4C). In a T lymphocyte proliferation assay, splenic T lymphocytes collected from allogeneic FM-MSC-transplanted EAM rats had a reduced proliferative response to myosin compared with the response of splenic T lymphocytes from untransplanted EAM rats. In addition, proliferation of activated T lymphocytes was suppressed by co-culture with allogeneic FM-MSCs *in vitro*.

Okada et al. reported that Th2-type cytokine expression in EAM was increased by HGF, whereas Th1-type cytokine expression was suppressed by intramyocardial transplantation of autologous BM-MSCs (Okada et al., 2007). An increase in HGF expression may reduce the severity of EAM by suppressing the Th1 response. Van Linthout et al. reported that MSCs improved murine acute coxsackievirus B3-induced myocarditis via their immunomodulatory properties in a nitric oxide-dependent manner (Van Linthout et al., 2010).

Fig. 3. Engraftment of allogeneic FM-MSCs and BM-MSCs injected into ischemic hindlimb muscles. (A) Representative sections show that GFP-positive allogeneic FM-MSCs and BM-MSCs were present in the hindlimb muscles of rats with hindlimb ischemia 1 and 3 weeks after cell injection (brown stain; black arrows). Scale bars: 50 μ m. (B) Quantitative analysis demonstrated that comparable numbers of GFP-positive allogeneic FM-MSCs and allogeneic BM-MSCs were observed in ischemic hindlimbs 1 week after cell injection. Three weeks after cell injection, a few GFP-positive allogeneic FM-MSCs and BM-MSCs were observed. Data are mean $\pm$ S.E.M.

Fig. 4. Histopathological changes in autoimmune myocarditis at 2 weeks after transplantation induced by transplantation of allogeneic FM-MSCs. (A) Myocardial sections showed markedly less inflammation in the allogeneic FM-MSCs transplanted group than in the untransplanted myocarditis group. Insets are transverse sections of the myocardium. The semiquantitative histological grade of edema and eosinophil infiltration were markedly decreased in the allogeneic FM-MSCs transplanted group. (B) CD68-positive macrophage/monocyte infiltration, and (C) CD3-positive T cell infiltration were markedly reduced by allogeneic FM-MSC transplantation. Scale bars = 50 μ m. Data are expressed as mean $\pm$ SEM. * P < 0.05 vs. the sham group; † P < 0.05 vs. the untreated myocarditis group.

Allogeneic transplantation of FM-MSCs may be an attractive therapy for the treatment of autoimmune myocarditis. Further studies are needed to elucidate the therapeutic mechanisms.

3. Potential of mesenchymal stem cell sheet transplantation therapy

As discussed above, MSC transplantation has attractive possibilities as a tool for cell transplantation therapy. However, further experiments are needed to develop data obtained with MSCs for application to humans because evidence of an ameliorating effect on angiogenesis and cardiac function is not necessarily sufficient to warrant clinical use. To date, intramuscular and intravenous injections have been used for cell transplantation therapy, but the engraftment rate of MSCs transplanted via these routes was very low (Ishikane et al. 2008, 2010). Although intramuscularly transplanted allogeneic FM-MSCs survived in ischemic hind-limb tissue for 3 weeks after transplantation, the number of engrafted cells decreased significantly. In EAM, some of the intravenously transplanted MSCs were found in the lung, heart, spleen and liver 1 week after transplantation, but these engrafted cells could not be detected 4 weeks after transplantation. Most homing and engraftment studies demonstrated little, if any, long-term (>1 week) engraftment of MSCs after systemic administration (Parekkadan and Milwid, 2010). Studies showed that the majority of administered MSCs (>80%) immediately accumulate in the lung and are cleared with a half-life of 24 h. Although intravenous cell transplantation is very convenient, it is not suitable for transplantation of large numbers of cells. Thus, a more effective transplantation route is needed to enhance angiogenesis and cardiac functional improvement in MSC transplantation.

Recently, cell sheet engineering received attention as a method for heart tissue repair. Okano et al. developed engineered cell sheets containing scaffoldless tissue using temperature-responsive culture dishes (Yamada et al., 1990). These cell sheets enable cell-to-cell connections and maintain the presence of adhesion proteins. The cell sheets preserve extracellular matrix proteins deposited on the basal surface of the cultured cells. These adhesive proteins play an important role in enhancing attachment between stacked cell sheets and between cell sheets and the myocardial surface, thereby enabling stable fixation of the cell sheet constructs to the target tissues. The cell sheets can readily be transferred and grafted to scarred myocardium without additives or suturing. Memon et al. demonstrated that layered skeletal myoblast sheets transplanted to infarcted rat hearts enhanced left ventricular contraction, reduced fibrosis and prevented left ventricular dilation (Memon et al., 2005). Kondoh et al. showed that in hamsters with dilated cardiomyopathy, myoblast sheet graft implantation improved cardiac performance and prolonged life expectancy in association with a reduction in myocardial fibrosis (Kondoh et al., 2006). In our study on rats, adipose tissue-derived MSC sheets improved cardiac function in damaged hearts, with reversal of cardiac wall thinning and prolonged survival after myocardial infarction (Miyahara et al., 2006). These cell sheets enable transplantation of many more cells than with intramuscular or intravenous needle injection. MSC sheet transplantation is expected to increase the number of engrafted cells and to enhance paracrine signaling.

4. Conclusion

This review shows the potential of allogeneic transplantation of FM-MSCs for the treatment of peripheral vascular disease and autoimmune myocarditis. FM-MSCs did not elicit

alloreactive T lymphocyte proliferation, and allogeneic FM-MSC transplantation induced therapeutic angiogenesis in a rat model of hind-limb ischemia. The angiogenic effects may be induced in a paracrine manner rather than via vascular differentiation of the transplanted MSCs. It is expected that allogeneic FM-MSC transplantation will be an effective therapy for autoimmune myocarditis with rapidly progressive heart failure. The beneficial effects of allogeneic FM-MSC transplantation are mainly attributable to suppression of T lymphocyte activation and anti-inflammatory effects. FM are potentially promising cell source for clinical use; they are medical waste material, are abundantly available from maternity wards. The unlimited availability of term gestational tissue, large number of cell that can be isolated from FM without invasive procedures, minimal ethical and legal barriers associated with their usage and immune tolerance make these cells highly attractive for stem cell based regenerative and reparative medicine and tissue engineering. Meanwhile, the risk of tumor formation from transplanting allogeneic FM-MSC into patients remains undetermined, and long-term follow-up studies are needed to clarify safety. Although further experiments are needed to adapt the current results for clinical application, we predict that allogeneic FM-MSC transplantation therapy will become a treatment for severe peripheral vascular disease and autoimmune myocarditis.

5. Acknowledgments

Our studies were supported by a Research Grant for Cardiovascular Disease (18C-1) and Human Genome Tissue Engineering 009 from the Ministry of Health, Labor and Welfare. We are grateful to Dr Kenichi Yamahara, Dr Makoto Kodama, Dr Hatsue Ishibashi-Ueda, Dr Shunsuke Ohnishi and Dr Noritoshi Nagaya for their support of our studies. We are thankful to the National BioResource Project for the Rat in Japan (<http://www.anim.med.kyoto-u.ac.jp/NBR/>) for providing rat strain LEW-TgN(CAG-EGFP)1Ys.

6. References

- Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood*, Vol.105, No.4, (October 2004), pp.1815-1822, ISSN 0006-4971
- Al-Khalidi, A.; Al-Sabti, H.; Galipeau, J., & Lachapelle, K. (2003). Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. *Annals of Thoracic Surgery*, Vol.75, No.1, (January 2003), pp.204-209, ISSN 0003-4975
- Alviano, F.; Fossati, V.; Marchionni, C.; Arpinati, M.; Bonsi, L.; Franchina, M.; Lanzoni, G.; Cantoni, S.; Cavallini, C.; Bianchi, F.; Tazzari, P. L.; Pasquinelli, G.; Foroni, L.; Ventura, C.; Grossi, A., & Bagnara, G. P. (2007). Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. *BMC Developmental Biology*, Vol.7, (February 2007), pp.11, ISSN 1471-213X
- Amado, L. C.; Saliaris, A. P.; Schuleri, K. H.; St John, M.; Xie, J. S.; Cattaneo, S.; Durand, D. J.; Fitton, T.; Kuang, J. Q.; Stewart, G.; Lehrke, S.; Baumgartner, W. W.; Martin, B. J.; Heldman, A. W., & Hare, J. M. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. *Proceedings of the*

- National Academy of Sciences of the United States of America*, Vol.102, No.32, (August 2005), pp.11474-11479, ISSN 0027-8424
- Aranguren, X. L.; McCue, J. D.; Hendrickx, B.; Zhu, X. H.; Du, F.; Chen, E.; Pelacho, B.; Penuelas, I.; Abizanda, G.; Uriz, M.; Frommer, S. A.; Ross, J. J.; Schroeder, B. A.; Seaborn, M. S.; Adney, J. R.; Hagenbrock, J.; Harris, N. H.; Zhang, Y.; Zhang, X.; Nelson-Holte, M. H.; Jiang, Y.; Billiau, A. D.; Chen, W.; Prosper, F.; Verfaillie, C. M., & Luttun, A. (2008). Multipotent adult progenitor cells sustain function of ischemic limbs in mice. *Journal of Clinical Investigation*, Vol.118, No.2, (January 2008), pp.505-514, ISSN 0021-9738
- Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwaguro, H.; Inai, Y.; Silver, M., & Isner, J. M. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *EMBO Journal*, Vol.18, No.14, (July 1999), pp.3964-3972, ISSN 0261-4189
- Au, P.; Tam, J.; Fukumura, D., & Jain, R. K. (2008). Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. *Blood*, Vol.111, No.9, (February 2008), pp.4551-4558, ISSN 1528-0020
- Bourne, G. (1962). The foetal membranes. A review of the anatomy of normal amnion and chorion and some aspects of their function. *Postgraduate Medical Journal*, Vol.38, (April 1962), pp.193-201, ISSN 0032-5473
- Campagnoli, C.; Roberts, I. A.; Kumar, S.; Bennett, P. R.; Bellantuono, I., & Fisk, N. M. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. *Blood*, Vol.98, No.8, (October 2001), pp.2396-2402, ISSN 0006-4971
- Caplan, A. I. (1991). Mesenchymal stem cells. *Journal of Orthopaedic Research*, Vol.9, No.5, (September 1991), pp.641-650, ISSN 0736-0266
- Carmeliet, P. (2003). Angiogenesis in health and disease. *Nature Medicine*, Vol.9, No.6, (June 2003), pp.653-660, ISSN 1078-8956
- Chabannes, D.; Hill, M.; Merieau, E.; Rossignol, J.; Brion, R.; Soullillou, J. P.; Anegon, I., & Cuturi, M. C. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. *Blood*, Vol.110, No.10, (August 2007), pp.3691-3694, ISSN 0006-4971
- Chamberlain, G.; Fox, J.; Ashton, B., & Middleton, J. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells*, Vol.25, No.11, (July 2007), pp.2739-2749, ISSN 1549-4918
- D'Ippolito, G.; Schiller, P. C.; Ricordi, C.; Roos, B. A., & Howard, G. A. (1999). Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. *Journal of Bone and Mineral Research*, Vol.14, No.7, (July 1999), pp.1115-1122, ISSN 0884-0431
- Dai, W.; Hale, S. L.; Martin, B. J.; Kuang, J. Q.; Dow, J. S.; Wold, L. E., & Kloner, R. A. (2005). Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. *Circulation*, Vol.112, No.2, (July 2005), pp.214-223, ISSN 1524-4539
- Di Nicola, M.; Carlo-Stella, C.; Magni, M.; Milanesi, M.; Longoni, P. D.; Matteucci, P.; Grisanti, S., & Gianni, A. M. (2002). Human bone marrow stromal cells suppress T-

- lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood*, Vol.99, No.10, (May 2002), pp.3838-3843, ISSN 0006-4971
- Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D., & Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*, Vol.8, No.4, (August 2006), pp.315-317, ISSN 1465-3249
- Fouillard, L.; Chapel, A.; Bories, D.; Bouchet, S.; Costa, J. M.; Rouard, H.; Herve, P.; Gourmelon, P.; Thierry, D.; Lopez, M., & Gorin, N. C. (2007). Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. *Leukemia*, Vol.21, No.3, (January 2007), pp.568-570, ISSN 0887-6924
- Friedenstein, A. J.; Chailakhyan, R. K.; Latsinik, N. V.; Panasyuk, A. F., & Keiliss-Borok, I. V. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation*, Vol.17, No.4, (April 1974), pp.331-340, ISSN 0041-1337
- Hare, J. M.; Traverse, J. H.; Henry, T. D.; Dib, N.; Strumpf, R. K.; Schulman, S. P.; Gerstenblith, G.; DeMaria, A. N.; Denktas, A. E.; Gammon, R. S.; Hermiller, J. B., Jr.; Reisman, M. A.; Schaer, G. L., & Sherman, W. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *Journal of the American College of Cardiology*, Vol.54, No.24, (December 2009), pp.2277-2286, ISSN 1558-3597
- In 't Anker, P. S.; Scherjon, S. A.; Kleijburg-van der Keur, C.; de Groot-Swings, G. M.; Claas, F. H.; Fibbe, W. E., & Kanhai, H. H. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells*, Vol.22, No.7, (December 2004), pp.1338-1345, ISSN 1066-5099
- Ishikane, S.; Ohnishi, S.; Yamahara, K.; Sada, M.; Harada, K.; Mishima, K.; Iwasaki, K.; Fujiwara, M.; Kitamura, S.; Nagaya, N., & Ikeda, T. (2008). Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. *Stem Cells*, Vol.26, No.10, (August 2008), pp.2625-2633, ISSN 1549-4918
- Ishikane, S.; Yamahara, K.; Sada, M.; Harada, K.; Kodama, M.; Ishibashi-Ueda, H.; Hayakawa, K.; Mishima, K.; Iwasaki, K.; Fujiwara, M.; Kangawa, K., & Ikeda, T. (2010). Allogeneic administration of fetal membrane-derived mesenchymal stem cells attenuates acute myocarditis in rats. *Journal of Molecular and Cellular Cardiology*, Vol.49, No.5, (August 2010), pp.753-761, ISSN 1095-8584
- Iwase, T.; Nagaya, N.; Fujii, T.; Itoh, T.; Murakami, S.; Matsumoto, T.; Kangawa, K., & Kitamura, S. (2005). Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. *Cardiovascular Research*, Vol.66, No.3, (May 2005), pp.543-551, ISSN 0008-6363
- Kim, J.; Kang, H. M.; Kim, H.; Kim, M. R.; Kwon, H. C.; Gye, M. C.; Kang, S. G.; Yang, H. S., & You, J. (2007). Ex vivo characteristics of human amniotic membrane-derived stem cells. *Cloning Stem Cells*, Vol.9, No.4, (December 2007), pp.581-594, ISSN 1536-2302
- Kim, S. W.; Han, H.; Chae, G. T.; Lee, S. H.; Bo, S.; Yoon, J. H.; Lee, Y. S.; Lee, K. S.; Park, H. K., & Kang, K. S. (2006). Successful stem cell therapy using umbilical cord blood-

- derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model. *Stem Cells*, Vol.24, No.6, (February 2006), pp.1620-1626, ISSN 1066-5099
- Kinnaird, T.; Stabile, E.; Burnett, M. S.; Lee, C. W.; Barr, S.; Fuchs, S., & Epstein, S. E. (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circulation Research*, Vol.94, No.5, (January 2004), pp.678-685, ISSN 1524-4571
- Kondoh, H.; Sawa, Y.; Miyagawa, S.; Sakakida-Kitagawa, S.; Memon, I. A.; Kawaguchi, N.; Matsuura, N.; Shimizu, T.; Okano, T., & Matsuda, H. (2006). Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters. *Cardiovascular Research*, Vol.69, No.2, (January 2006), pp.466-475, ISSN 0008-6363
- Kopen, G. C.; Prockop, D. J., & Phinney, D. G. (1999). Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.96, No.19, (September 1999), pp.10711-10716, ISSN 0027-8424
- Kraitchman, D. L.; Tatsumi, M.; Gilson, W. D.; Ishimori, T.; Kedziorek, D.; Walczak, P.; Segars, W. P.; Chen, H. H.; Fritzges, D.; Izbudak, I.; Young, R. G.; Marcelino, M.; Pittenger, M. F.; Solaiyappan, M.; Boston, R. C.; Tsui, B. M.; Wahl, R. L., & Bulte, J. W. (2005). Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. *Circulation*, Vol.112, No.10, (September 2005), pp.1451-1461, ISSN 1524-4539
- Krampera, M.; Glennie, S.; Dyson, J.; Scott, D.; Laylor, R.; Simpson, E., & Dazzi, F. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. *Blood*, Vol.101, No.9, (December 2002), pp.3722-3729, ISSN 0006-4971
- Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M. E.; Remberger, M.; Dini, G.; Egeler, R. M.; Bacigalupo, A.; Fibbe, W., & Ringden, O. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet*, Vol.371, No.9624, (May 2008), pp.1579-1586, ISSN 1474-547X
- Le Blanc, K.; Tammik, C.; Rosendahl, K.; Zetterberg, E., & Ringden, O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Experimental Hematology*, Vol.31, No.10, (October 2003), pp.890-896, ISSN 0301-472X
- Mareschi, K.; Ferrero, I.; Rustichelli, D.; Aschero, S.; Gammaitoni, L.; Aglietta, M.; Madon, E., & Fagioli, F. (2006). Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. *Journal of Cellular Biochemistry*, Vol.97, No.4, (October 2005), pp.744-754, ISSN 0730-2312
- Meisel, R.; Zibert, A.; Laryea, M.; Gobel, U.; Daubener, W., & Dilloo, D. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. *Blood*, Vol.103, No.12, (March 2004), pp.4619-4621, ISSN 0006-4971

- Memon, I. A.; Sawa, Y.; Fukushima, N.; Matsumiya, G.; Miyagawa, S.; Taketani, S.; Sakakida, S. K.; Kondoh, H.; Aleshin, A. N.; Shimizu, T.; Okano, T., & Matsuda, H. (2005). Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. *Journal of Thoracic and Cardiovascular Surgery*, Vol.130, No.5, (November 2005), pp.1333-1341, ISSN 1097-685X
- Miyahara, Y.; Nagaya, N.; Kataoka, M.; Yanagawa, B.; Tanaka, K.; Hao, H.; Ishino, K.; Ishida, H.; Shimizu, T.; Kangawa, K.; Sano, S.; Okano, T.; Kitamura, S., & Mori, H. (2006). Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. *Nature Medicine*, Vol.12, No.4, (April 2006), pp.459-465, ISSN 1078-8956
- Moon, M. H.; Kim, S. Y.; Kim, Y. J.; Kim, S. J.; Lee, J. B.; Bae, Y. C.; Sung, S. M., & Jung, J. S. (2006). Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. *Cellular Physiology and Biochemistry*, Vol.17, No.5-6, (June 2006), pp.279-290, ISSN 1015-8987
- Morishita, R.; Nakamura, S.; Hayashi, S.; Taniyama, Y.; Moriguchi, A.; Nagano, T.; Taiji, M.; Noguchi, H.; Takeshita, S.; Matsumoto, K.; Nakamura, T.; Higaki, J., & Ogihara, T. (1999). Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. *Hypertension*, Vol.33, No.6, (June 1999), pp.1379-1384, ISSN 0194-911X
- Muller-Ehmsen, J.; Krausgrill, B.; Burst, V.; Schenk, K.; Neisen, U. C.; Fries, J. W.; Fleischmann, B. K.; Hescheler, J., & Schwinger, R. H. (2006). Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. *Journal of Molecular and Cellular Cardiology*, Vol.41, No.5, (September 2006), pp.876-884, ISSN 0022-2828
- Nagaya, N.; Kangawa, K.; Itoh, T.; Iwase, T.; Murakami, S.; Miyahara, Y.; Fujii, T.; Uematsu, M.; Ohgushi, H.; Yamagishi, M.; Tokudome, T.; Mori, H.; Miyatake, K., & Kitamura, S. (2005). Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. *Circulation*, Vol.112, No.8, (August 2005), pp.1128-1135, ISSN 1524-4539
- Nakagami, H.; Maeda, K.; Morishita, R.; Iguchi, S.; Nishikawa, T.; Takami, Y.; Kikuchi, Y.; Saito, Y.; Tamai, K.; Ogihara, T., & Kaneda, Y. (2005). Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, Vol.25, No.12, (October 2005), pp.2542-2547, ISSN 1524-4636
- Ohnishi, S.; Yanagawa, B.; Tanaka, K.; Miyahara, Y.; Obata, H.; Kataoka, M.; Kodama, M.; Ishibashi-Ueda, H.; Kangawa, K.; Kitamura, S., & Nagaya, N. (2007). Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. *Journal of Molecular and Cellular Cardiology*, Vol.42, No.1, (November 2006), pp.88-97, ISSN 0022-2828
- Okada, H.; Suzuki, J.; Futamatsu, H.; Maejima, Y.; Hirao, K., & Isobe, M. (2007). Attenuation of autoimmune myocarditis in rats by mesenchymal stem cell transplantation through enhanced expression of hepatocyte growth factor. *International Heart Journal*, Vol.48, No.5, (November 2007), pp.649-661, ISSN 1349-2365
- Parekkadan, B., & Milwid, J. M. (2010). Mesenchymal stem cells as therapeutics. *Annual Reviews Biomedical Engineering*, Vol.12, (April 2010), pp.87-117, ISSN 1545-4274

- Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R. K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; Craig, S., & Marshak, D. R. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science*, Vol.284, No.5411, (April 1999), pp.143-147, ISSN 0036-8075
- Portmann-Lanz, C. B.; Schoeberlein, A.; Huber, A.; Sager, R.; Malek, A.; Holzgreve, W., & Surbek, D. V. (2006). Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. *American Journal of Obstetrics and Gynecology*, Vol.194, No.3, (March 2006), pp.664-673, ISSN 1097-6868
- Sensebe, L.; Krampera, M.; Schrezenmeier, H.; Bourin, P., & Giordano, R. (2010). Mesenchymal stem cells for clinical application. *Vox Sanguinis*, Vol.98, No.2, (August 2009), pp.93-107, ISSN 1423-0410
- Shake, J. G.; Gruber, P. J.; Baumgartner, W. A.; Senechal, G.; Meyers, J.; Redmond, J. M.; Pittenger, M. F., & Martin, B. J. (2002). Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. *Annals of Thoracic Surgery*, Vol.73, No.6, (June 2002), pp.1919-1925; discussion 1926, ISSN 0003-4975
- Sioud, M.; Mobergslien, A.; Boudabous, A., & Floisand, Y. (2011). Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. *International Journal of Oncology*, Vol.38, No.2, (December 2010), pp.385-390, ISSN 1791-2423
- Soncini, M.; Vertua, E.; Gibelli, L.; Zorzi, F.; Denegri, M.; Albertini, A.; Wengler, G. S., & Parolini, O. (2007). Isolation and characterization of mesenchymal cells from human fetal membranes. *Journal of Tissue Engineering and Regenerative Medicine*, Vol.1, No.4, (November 2007), pp.296-305, ISSN 1932-6254
- Van Linthout, S.; Savvatis, K.; Miteva, K.; Peng, J.; Ringe, J.; Warstat, K.; Schmidt-Lucke, C.; Sittlinger, M.; Schultheiss, H. P., & Tschope, C. (2010). Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. *European Heart Journal*, in press, (December 2010), ISSN 1522-9645
- Weimar, I. S.; Miranda, N.; Muller, E. J.; Hekman, A.; Kerst, J. M.; de Gast, G. C., & Gerritsen, W. R. (1998). Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). *Experimental Hematology*, Vol.26, No.9, (August 1998), pp.885-894, ISSN 0301-472X
- Yamada, M.; Koeda, T.; Kikuchi, H.; Nasu, M.; Isagozawa, S.; Mukaida, H.; Yosida, H.; Ahsan, R.; Otokida, K., & Kato, M. (1990). Evaluation of increasing digital blood flow during early period of air-cooled cold test]. *Kokyu to Junkan. Respiration and Circulation*, Vol.38, No.6, (June 1990), pp.571-576, ISSN 0452-3458
- Zarnegar, R., & Michalopoulos, G. K. (1995). The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. *Journal of Cell Biology*, Vol.129, No.5, (June 1995), pp.1177-1180, ISSN 0021-9525
- Zuk, P. A.; Zhu, M.; Mizuno, H.; Huang, J.; Futrell, J. W.; Katz, A. J.; Benhaim, P.; Lorenz, H. P., & Hedrick, M. H. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Engineering*, Vol.7, No.2, (April 2001), pp.211-228, ISSN 1076-3279

Tissue Regeneration - From Basic Biology to Clinical Application

Edited by Prof. Jamie Davies

ISBN 978-953-51-0387-5

Hard cover, 512 pages

Publisher InTech

Published online 30, March, 2012

Published in print edition March, 2012

When most types of human tissue are damaged, they repair themselves by forming a scar - a mechanically strong 'patch' that restores structural integrity to the tissue without restoring physiological function. Much better, for a patient, would be like-for-like replacement of damaged tissue with something functionally equivalent: there is currently an intense international research effort focused on this goal. This timely book addresses key topics in tissue regeneration in a sequence of linked chapters, each written by world experts; understanding normal healing; sources of, and methods of using, stem cells; construction and use of scaffolds; and modelling and assessment of regeneration. The book is intended for an audience consisting of advanced students, and research and medical professionals.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Shin Ishikane, Hiroshi Hosoda and Tomoaki Ikeda (2012). Therapeutic Application of Allogeneic Fetal Membrane-Derived Mesenchymal Stem Cell Transplantation in Regenerative Medicine, Tissue Regeneration - From Basic Biology to Clinical Application, Prof. Jamie Davies (Ed.), ISBN: 978-953-51-0387-5, InTech, Available from: <http://www.intechopen.com/books/tissue-regeneration-from-basic-biology-to-clinical-application/therapeutic-application-of-fetal-membrane-derived-mesenchymal-stem-cells-transplantation-in-regenera>

INTech
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen